Literature DB >> 15299839

Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506.

D M Armistead1, M C Badia, D D Deininger, J P Duffy, J O Saunders, R D Tung, J A Thomson, M T DeCenzo, O Futer, D J Livingston, M A Murcko, M M Yamashita, M A Navia.   

Abstract

We have synthesized a series of non-macrocyclic ligands to FKBP12 that are comparable in binding potency and peptidyl prolyl isomerase (PPIase) inhibition to FK506 itself. We have also solved the structure of one of these ligands in complex with FKBP12, and have compared that structure to the FK506-FKBP12 complex. Consistent with the observed inhibitory equipotency of these compounds, we observe a strong similarity in the conformation of the two ligands in the region of the protein that mediates PPIase activity. Our compounds, however, are not immunosuppressive. In the FKBP12-FK506 complex, a significant portion of the FK506 ligand, its 'effector domain', projects beyond the envelope of the binding protein in a manner that is suggestive of a potential interaction with a second protein, the calcium-dependent phosphatase, calcineurin, whose inhibition by the FKBP 12-FK506 complex interrupts the T-cell activation events leading to immunosuppression. In contrast, our compounds bind within the surface envelope of FKBP12, and induce significant changes in the structure of the FKBP12 protein which may also affect calcineurin binding indirectly.

Entities:  

Year:  1995        PMID: 15299839     DOI: 10.1107/S0907444994014502

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  14 in total

1.  A multiplexed proteomics approach to differentiate neurite outgrowth patterns.

Authors:  Tong Liu; Veera D'mello; Longwen Deng; Jun Hu; Michael Ricardo; Sanqiang Pan; Xiaodong Lu; Scott Wadsworth; John Siekierka; Raymond Birge; Hong Li
Journal:  J Neurosci Methods       Date:  2006-06-23       Impact factor: 2.390

2.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Authors:  T Clackson; W Yang; L W Rozamus; M Hatada; J F Amara; C T Rollins; L F Stevenson; S R Magari; S A Wood; N L Courage; X Lu; F Cerasoli; M Gilman; D A Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  Calcineurin determines toxic versus beneficial responses to α-synuclein.

Authors:  Gabriela Caraveo; Pavan K Auluck; Luke Whitesell; Chee Yeun Chung; Valeriya Baru; Eugene V Mosharov; Xiaohui Yan; Manu Ben-Johny; Martin Soste; Paola Picotti; Hanna Kim; Kim A Caldwell; Guy A Caldwell; David Sulzer; David T Yue; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-13       Impact factor: 11.205

Review 4.  Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets.

Authors:  Can M Ünal; Michael Steinert
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

Review 5.  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.

Authors:  Bryan M Dunyak; Jason E Gestwicki
Journal:  J Med Chem       Date:  2016-07-25       Impact factor: 7.446

Review 6.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

7.  The utility of geometrical and chemical restraint information extracted from predicted ligand-binding sites in protein structure refinement.

Authors:  Michal Brylinski; Seung Yup Lee; Hongyi Zhou; Jeffrey Skolnick
Journal:  J Struct Biol       Date:  2010-09-17       Impact factor: 2.867

Review 8.  Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies.

Authors:  John Koren; Umesh K Jinwal; Zachary Davey; Janine Kiray; Karthik Arulselvam; Chad A Dickey
Journal:  Mol Neurobiol       Date:  2011-04-28       Impact factor: 5.590

9.  The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response.

Authors:  Alexa Klettner; Thomas Herdegen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus).

Authors:  S Itoh; M A Navia
Journal:  Protein Sci       Date:  1995-11       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.